CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Merck licenses a KRAS G12D inhibitor for $400M upfront

Related Companies

Read the original article

Published by Endpoints News on September 28, 2026 2:00 PM

Read Original